Chr. Hansen
| Company type | Publicly traded Aktieselskab |
|---|---|
| Nasdaq Copenhagen: CHR | |
| ISIN | DK0060227585 |
| Industry | Biotechnology |
| Founded | 1874 |
| Defunct | January 29, 2024 |
| Fate | Merged with Novozymes |
| Successor | Novonesis |
| Headquarters | Hørsholm, Denmark |
Key people | Dominique Reiniche (Chair), Mauricio Graber (President and CEO) |
| Products | microbiological cultures, enzymes, probiotics, Human milk oligosaccharides |
| Revenue | €1,218 million (2022) |
| €326 million (2022) | |
| €225 million (2022) | |
| Total assets | €3,317 million (2022) |
| Total equity | €181 million |
Number of employees | 3,834 (2021-2022) |
| Website | Archived 2 January 2024 at the Wayback Machine |
| Footnotes / references | |
Chr. Hansen A/S was a biotechnology company based in Hørsholm, Denmark. The company is a supplier of bacteria cultures, probiotics, enzymes and human milk oligosaccharides. Its products are used in the production of fresh dairy, cheese, meat, seafood, fermented beverages, dairy and meat alternatives, dietary supplements, infant formula, pharmaceuticals and agricultural products. In 2021, Chr. Hansen A/S was ranked 1st on FoodTalks' Top 30 Global Probiotic Food Ingredient Companies list. Chr. Hansen owns one of the world's largest commercial bacteria collections. The company merged with Novozymes to form Novonesis in January 2024.
Chr. Hansen A/S has development centers in Denmark, the United States, France and Germany including research facilities in Denmark and France. A large percentage of the employees engage in research and development for the international food and pharmaceuticals industries.
Chr. Hansen A/S has five main production sites: two in Denmark and Germany (Nienburg and Pohlheim) and one each in France (Arpajon) and the US (West Allis, WI) and an international presence in 30 countries. It was previously listed on Nasdaq OMX Copenhagen under the symbol "CHR".